CONMED Corp (CNMD) stock
Close on Nov 12, 2026Market cap $1.50BP/E 20.9Yield 1.19%
CONMED Corp grew revenue 1.6% to $1.37B over the twelve months to Sep 30, 2026. Operating income rose 14.4% to $135.59M, moving the operating margin from 8.8% to 9.9%. Free cash flow was $132.69M, down 10.9% from a year earlier. At the latest close the market valued the company at $1.50B, 20.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.50B
- P/E ratio
- 20.9
- Price to sales
- 1.10
- Price to book
- 1.42
- Dividend yield
- 1.19%
- Free cash flow yield
- 8.82%
Fundamentals
- Revenue
- $1.37B
- Net income
- $73.43M
- EPS, diluted
- $2.42
- Free cash flow
- $132.69M
- Book value per share
- $35.18
- Diluted shares
- 30M
Trading
- Next earnings
- Jan 27, 2027 (estimated, during market hours)
- Previous close
- $50.77
- Open
- $51.43
- Day's range
- $50.17 – $51.43
- Volume
- 217,926
- Average volume (20 days)
- 403,953
- Index membership
- S&P SmallCap 600, Russell 2000, Russell 3000
- Beta (5 years)
- 0.94
- 52-week range
- $31.44 – $54.80
- RSI (14 days)
- 56.5
- Volatility (1 year)
- 47.0%
- Relative volume
- 0.46×
- WACC
- 7.4%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CNMD | S&P 500 | Difference | CNMD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.3% | -2.7% | +14.0 pts | ||
| 3 months | +2.0% | -1.7% | +3.8 pts | ||
| Year to date | +24.3% | +11.9% | +12.4 pts | ||
| 1 year | +15.9% | +12.0% | +3.9 pts | ||
| 3 years | -47.6% | +78.2% | −125.7 pts | -19.4% | +21.2% |
| 5 years | -65.4% | +73.2% | −138.6 pts | -19.1% | +11.6% |
| 10 years | +24.3% | +309.6% | −285.3 pts | +2.2% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Conmed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About Conmed
Electromedical & Electrotherapeutic Apparatus
CONMED Corporation is a medical technology company that develops, manufactures, and distributes surgical equipment and clinical devices. The firm operates primarily through two segments: orthopedic surgery and general surgery. Its orthopedic solutions include soft tissue repair implants, sports medicine fixation hardware, visualization tools, and powered bone cutting systems. The general surgery segment supplies smoke evacuation equipment, insufflation systems, electrosurgical generators, endomechanical instruments, and endoscopic devices. These products serve healthcare providers and surgeons across disciplines such as orthopedics, gynecology, thoracic surgery, and gastroenterology, along with hospitals and surgical centers.
Company profile, executives and historyConmed stock: common questions
What is Conmed's stock price?
CNMD closed at $50.48 on Nov 12, 2026, down 0.57% on the day. Over the past 52 weeks it traded between $31.44 and $54.80.
What is Conmed's market cap?
Conmed was worth $1.50B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CNMD's P/E ratio?
CNMD trades at 20.9 times earnings, based on diluted earnings per share of $2.42 over the twelve months to Sep 30, 2026.
How much revenue does Conmed make?
Conmed reported revenue of $1.37B for the twelve months to Sep 30, 2026, up 1.6% from a year earlier.
Does Conmed pay a dividend?
Yes. Conmed paid $0.60 per share over the last twelve months, a yield of 1.19% at the latest price.
When does Conmed report earnings next?
Conmed is expected to report Q4 FY2026 results on Jan 27, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CNMD stock performed over the past year?
Including dividends, CNMD returned +15.9% over the past year, against +12.0% for the S&P 500.
How many CNMD shares are sold short?
2M shares were sold short at the latest FINRA report, 6.27% of the float, or 4.3 days of average trading volume.
Who are Conmed's competitors?
Companies most similar to Conmed by business, industry and size include LIVN, ITGR, HAE, TFX, ENOV.
See a number that looks wrong?